Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

RNA Interference Therapy with ARC-520 Results in Prolonged HBsAg Response in Patients with Chronic Hepatitis B Infection.

Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Chan HLY, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG.

Hepatology. 2019 Oct 26. doi: 10.1002/hep.31008. [Epub ahead of print]

PMID:
31654573
2.

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.

Walsh R, Hammond R, Yuen L, Deerain J, O'Donnell T, Leary T, Cloherty G, Gaggar A, Kitrinos K, Subramanian M, Wong D, Locarnini S.

Liver Int. 2019 Nov;39(11):2066-2076. doi: 10.1111/liv.14207. Epub 2019 Aug 21.

PMID:
31379058
3.

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members.

J Hepatol. 2019 Aug;71(2):397-408. doi: 10.1016/j.jhep.2019.03.034. Epub 2019 Apr 18. Review.

4.

Diagnostics of Hepatitis B Virus: Standard of Care and Investigational.

Jackson K, Locarnini S, Gish R.

Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):5-11. doi: 10.1002/cld.729. eCollection 2018 Jul. Review. No abstract available.

5.

Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.

Jackson K, Holgate T, Tekoaua R, Nicholson S, Littlejohn M, Locarnini S.

J Med Virol. 2019 Apr 12. doi: 10.1002/jmv.25485. [Epub ahead of print]

PMID:
30977903
6.

Tracing Ancient Human Migrations into Sahul Using Hepatitis B Virus Genomes.

Yuen LKW, Littlejohn M, Duchêne S, Edwards R, Bukulatjpi S, Binks P, Jackson K, Davies J, Davis JS, Tong SYC, Locarnini S.

Mol Biol Evol. 2019 May 1;36(5):942-954. doi: 10.1093/molbev/msz021.

PMID:
30856252
7.

Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.

Kingston NJ, Kurtovic L, Walsh R, Joe C, Lovrecz G, Locarnini S, Beeson JG, Netter HJ.

Vaccine. 2019 Mar 14;37(12):1674-1684. doi: 10.1016/j.vaccine.2019.01.056. Epub 2019 Feb 14.

PMID:
30773400
8.

Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia.

Turpin J, Yurick D, Khoury G, Pham H, Locarnini S, Melamed A, Witkover A, Wilson K, Purcell D, Bangham CRM, Einsiedel L.

J Infect Dis. 2019 Jan 29;219(4):562-567. doi: 10.1093/infdis/jiy546.

9.

How infectious is the hepatitis B virus? Readings from the occult.

Locarnini S, Raimondo G.

Gut. 2019 Feb;68(2):182-183. doi: 10.1136/gutjnl-2018-316900. Epub 2018 Aug 1. No abstract available.

PMID:
30068661
10.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

Bannister EG, Yuen L, Littlejohn M, Edwards R, Sozzi V, Colledge D, Li X, Locarnini S, Hardikar W, Revill PA.

J Gen Virol. 2018 Aug;99(8):1103-1114. doi: 10.1099/jgv.0.001086. Epub 2018 Jun 22.

PMID:
29932395
11.

Hepatitis B virus infection.

Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL.

Nat Rev Dis Primers. 2018 Jun 7;4:18035. doi: 10.1038/nrdp.2018.35. Review.

PMID:
29877316
12.

Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia.

Jackson K, MacLachlan J, Cowie B, Locarnini S, Bowden S, Higgins N, Karapanagiotidis T, Nicholson S, Littlejohn M.

Intern Med J. 2018 Nov;48(11):1308-1317. doi: 10.1111/imj.13967.

PMID:
29761607
13.

Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.

Cheah BC, Davies J, Singh GR, Wood N, Jackson K, Littlejohn M, Davison B, McIntyre P, Locarnini S, Davis JS, Tong SYC.

Vaccine. 2018 Jun 7;36(24):3533-3540. doi: 10.1016/j.vaccine.2018.01.062. Epub 2018 May 4.

PMID:
29735323
14.

In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease.

Sozzi V, Shen F, Chen J, Colledge D, Jackson K, Locarnini S, Yuan Z, Revill PA.

Virology. 2018 Jun;519:190-196. doi: 10.1016/j.virol.2018.04.015. Epub 2018 May 4.

15.

Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing.

Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT.

Liver Int. 2018 Jul;38(7):1212-1219. doi: 10.1111/liv.13736. Epub 2018 Mar 31.

PMID:
29532580
16.

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.

Wong D, Littlejohn M, Edwards R, Jackson K, Revill P, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti-Ferret M, Janssen H, Gane E, Locarnini S, Thompson A.

Liver Int. 2018 Oct;38(10):1760-1769. doi: 10.1111/liv.13716. Epub 2018 Mar 6.

PMID:
29427368
17.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

18.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaan0241. doi: 10.1126/scitranslmed.aan0241.

19.

A research agenda for curing chronic hepatitis B virus infection.

Alter H, Block T, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Chisari FV, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten T, Guo H, Guo JT, Hoshida Y, Hu J, Kowdley KV, Li W, Liang J, Locarnini S, Lok AS, Mason W, McMahon B, Mehta A, Perrillo R, Revill P, Rice CM, Rinaudo J, Schinazi R, Seeger C, Shetty K, Tavis J, Zoulim F.

Hepatology. 2018 Mar;67(3):1127-1131. doi: 10.1002/hep.29509. Epub 2018 Jan 24. No abstract available.

20.

The virological aspects of hepatitis B.

Valaydon ZS, Locarnini SA.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):257-264. doi: 10.1016/j.bpg.2017.04.013. Epub 2017 May 5. Review.

PMID:
28774407
21.

More than a virus: a qualitative study of the social implications of hepatitis B infection in China.

Wallace J, Pitts M, Liu C, Lin V, Hajarizadeh B, Richmond J, Locarnini S.

Int J Equity Health. 2017 Aug 1;16(1):137. doi: 10.1186/s12939-017-0637-4.

22.

New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.

Peters MG, Locarnini S.

Gastroenterol Hepatol (N Y). 2017 Jun;13(6):348-356.

23.

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG.

Clin Infect Dis. 2017 May 1;64(9):1283-1288. doi: 10.1093/cid/cix129. Review.

24.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro.

Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, Svicher V.

Oncotarget. 2017 Feb 28;8(9):15704-15715. doi: 10.18632/oncotarget.14944.

25.

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.

Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P.

Liver Int. 2017 Jun;37(6):827-835. doi: 10.1111/liv.13331. Epub 2016 Dec 22.

PMID:
27896895
26.

Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.

Thompson A, Locarnini S, Revill P.

Gut. 2017 Aug;66(8):1534-1535. doi: 10.1136/gutjnl-2016-313287. Epub 2016 Nov 24. No abstract available.

PMID:
27884921
27.

Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis.

Colledge D, Soppe S, Yuen L, Selleck L, Walsh R, Locarnini S, Warner N.

Virology. 2017 Jan 15;501:70-78. doi: 10.1016/j.virol.2016.11.007. Epub 2016 Nov 19.

28.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes.

Sozzi V, Walsh R, Littlejohn M, Colledge D, Jackson K, Warner N, Yuen L, Locarnini SA, Revill PA.

J Virol. 2016 Oct 28;90(22):10054-10064. doi: 10.1128/JVI.01293-16. Print 2016 Nov 15.

29.

Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).

Revill P, Locarnini S.

Curr Opin Pharmacol. 2016 Oct;30:144-150. doi: 10.1016/j.coph.2016.08.015. Review.

PMID:
27639371
30.

Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362. doi: 10.1002/cpdd.318. Epub 2016 Dec 12.

31.

World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015.

Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A; Review Team:.

J Clin Gastroenterol. 2016 Oct;50(9):691-703. doi: 10.1097/MCG.0000000000000647. No abstract available.

PMID:
27623512
32.

The role of quantitative hepatitis B surface antigen revisited.

Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL.

J Hepatol. 2017 Feb;66(2):398-411. doi: 10.1016/j.jhep.2016.08.009. Epub 2016 Aug 27. Review.

PMID:
27575311
33.

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.

Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA.

Gut. 2017 Nov;66(11):2013-2023. doi: 10.1136/gutjnl-2015-309300. Epub 2016 Aug 17.

PMID:
27534671
34.

No more excuses: viral hepatitis can be eliminated.

Locarnini S, Chen DS, Shibuya K.

Lancet. 2016 Apr 23;387(10029):1703-4. doi: 10.1016/S0140-6736(16)30295-1. No abstract available.

PMID:
27116263
35.

Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.

Audsley J, Bent SJ, Littlejohn M, Avihingsanon A, Matthews G, Bowden S, Bayliss J, Luciani F, Yuen L, Fairley CK, Locarnini S, Lewin SR, Sasadeusz J.

AIDS. 2016 Jun 19;30(10):1597-606. doi: 10.1097/QAD.0000000000001080.

PMID:
26950313
36.

Global strategies are required to cure and eliminate HBV infection.

Revill P, Testoni B, Locarnini S, Zoulim F.

Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):239-48. doi: 10.1038/nrgastro.2016.7. Epub 2016 Feb 24. Review.

PMID:
26907881
37.

New perspectives on the hepatitis B virus life cycle in the human liver.

Revill PA, Locarnini SA.

J Clin Invest. 2016 Mar 1;126(3):833-6. doi: 10.1172/JCI86650. Epub 2016 Feb 22.

38.

Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

Littlejohn M, Locarnini S, Yuen L.

Cold Spring Harb Perspect Med. 2016 Jan 4;6(1):a021360. doi: 10.1101/cshperspect.a021360. Review.

39.

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.

Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J.

Sci Rep. 2015 Nov 24;5:17123. doi: 10.1038/srep17123.

40.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH.

Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.

41.

Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.

Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA.

J Viral Hepat. 2016 Mar;23(3):170-9. doi: 10.1111/jvh.12477. Epub 2015 Oct 5.

PMID:
26436722
42.

Essential components in developing public policy to control viral hepatitis: lessons from Taiwan.

Wallace J, Pitts M, Locarnini S, Ellard J, Carman M, Chen DS.

Hepatol Int. 2016 Mar;10(2):355-62. doi: 10.1007/s12072-015-9660-y. Epub 2015 Sep 4.

PMID:
26341513
43.

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.

Hyakumura M, Walsh R, Thaysen-Andersen M, Kingston NJ, La M, Lu L, Lovrecz G, Packer NH, Locarnini S, Netter HJ.

J Virol. 2015 Nov;89(22):11312-22. doi: 10.1128/JVI.01123-15. Epub 2015 Sep 2.

44.

CD4+ T Cells Are Not Required for Suppression of Hepatitis B Virus Replication in the Liver of Vaccinated Chimpanzees.

Rybczynska J, Campbell K, Kamili S, Locarnini S, Krawczynski K, Walker CM.

J Infect Dis. 2016 Jan 1;213(1):49-56. doi: 10.1093/infdis/jiv348. Epub 2015 Aug 31.

45.

Present and future therapies of hepatitis B: From discovery to cure.

Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS.

Hepatology. 2015 Dec;62(6):1893-908. doi: 10.1002/hep.28025. Epub 2015 Oct 27. Review.

46.

Estimating the global prevalence of hepatitis B.

MacLachlan JH, Locarnini S, Cowie BC.

Lancet. 2015 Oct 17;386(10003):1515-7. doi: 10.1016/S0140-6736(15)61116-3. Epub 2015 Jul 28. No abstract available.

PMID:
26231458
47.

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, Locarnini SA, Lau JY, Wooddell CI, Schluep T, Lewis DL.

Antiviral Res. 2015 Sep;121:97-108. doi: 10.1016/j.antiviral.2015.06.019. Epub 2015 Jun 27. Review.

48.

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.

Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T.

Antiviral Res. 2015 Sep;121:47-58. doi: 10.1016/j.antiviral.2015.06.008. Epub 2015 Jun 16. Review.

PMID:
26092643
49.

From the big three to the big four.

Chen DS, Locarnini S, Wallace J.

Lancet Infect Dis. 2015 Jun;15(6):626-7. doi: 10.1016/S1473-3099(15)00026-2. Epub 2015 May 17. No abstract available.

PMID:
26008824
50.

Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

Locarnini S, Hatzakis A, Chen DS, Lok A.

J Hepatol. 2015 Apr;62(1 Suppl):S76-86. doi: 10.1016/j.jhep.2015.01.018. Review.

Supplemental Content

Loading ...
Support Center